Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Plaque Psoriasis Patients with Inadequate Response to Cyclosporine A
NCT02547714Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2015
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab in plaque psoriasis, sponsored by Novartis. Started Jun 2015; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02547714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547714.